Dr Pantziarka speaks with ecancertv at ESMO 2016 about current efforts, and regulatory hurdles, towards the repurposing of medicines that are approved to treat other diseases, but have the potential to improve cancer patient outcomes.

He discusses how propranolol, a beta-blocker commonly prescribed to treat hypertension, might be a cheap and effective adjuvant in cancer therapy.

Dr Pantziarka is also joined by Dr Lydie Meheus of The Anticancer Fund, Belgium.

Read Dr Pantziarka and Dr Meheus’ article Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent here.

Drug repurposing was discussed further at a joint meeting of the BACR and ECMC, reported by ecancer here.